Sunshine Operating Profit Margin from 2010 to 2025

SBFMW Stock  USD 0.20  0.01  4.76%   
Sunshine Biopharma Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin will likely drop to -0.19 in 2025. During the period from 2010 to 2025, Sunshine Biopharma Operating Profit Margin regression line of quarterly data had mean square error of  15,691 and geometric mean of  14.87. View All Fundamentals
 
Operating Profit Margin  
First Reported
2010-12-31
Previous Quarter
(0.18)
Current Value
(0.19)
Quarterly Volatility
225.55599709
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Operating Profit Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Operating Profit Margin10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Sunshine Operating Profit Margin Regression Statistics

Arithmetic Mean(175.03)
Geometric Mean14.87
Coefficient Of Variation(128.86)
Mean Deviation211.35
Median(8.08)
Standard Deviation225.56
Sample Variance50,876
Range457
R-Value0.84
Mean Square Error15,691
R-Squared0.71
Significance0.00004
Slope39.98
Total Sum of Squares763,133

Sunshine Operating Profit Margin History

2025 -0.19
2024 -0.18
2023 -0.2
2022 -2.0
2021 -10.68
2020 -8.08
2019 -30.38

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Operating Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Profit Margin(0.18)(0.19)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.